Trial · NCT02015065
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With a Clinical Activity-radiographic Response | 200 mg Vandetanib Adult | Complete Response | 0 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | 300 mg Vandetanib Adult | Complete Response | 0 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | Dose Level 100mg/m^2 Vandetanib Pediatric | Complete Response | 0 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | 200 mg Vandetanib Adult | Partial Response | 0 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | 300 mg Vandetanib Adult | Partial Response | 0 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | Dose Level 100mg/m^2 Vandetanib Pediatric | Partial Response | 0 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | 200 mg Vandetanib Adult | Stable Disease | 1 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | 300 mg Vandetanib Adult | Stable Disease | 2 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | Dose Level 100mg/m^2 Vandetanib Pediatric | Stable Disease | 1 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | 200 mg Vandetanib Adult | Progressive Disease | 1 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | 300 mg Vandetanib Adult | Progressive Disease | 3 | Participants | |
| Number of Participants With a Clinical Activity-radiographic Response | Dose Level 100mg/m^2 Vandetanib Pediatric | Progressive Disease | 1 | Participants | |
| Count of Participants With Serious and Non-serious Adverse Events | 200 mg Vandetanib Adult | 2 | Participants | ||
| Count of Participants With Serious and Non-serious Adverse Events | 300 mg Vandetanib Adult | 5 | Participants | ||
| Count of Participants With Serious and Non-serious Adverse Events | Dose Level 100mg/m^2 Vandetanib Pediatric | 2 | Participants | ||
| Percentage of Participants Overall Survival | 200 mg Vandetanib Adult | 50 | 95% Confidence Interval 0.6 to 91 | percentage of participants | |
| Percentage of Participants Overall Survival | 300 mg Vandetanib Adult | 60 | 95% Confidence Interval 12.6 to 88.2 | percentage of participants | |
| Percentage of Participants Overall Survival | Dose Level 100mg/m^2 Vandetanib Pediatric | 50 | 95% Confidence Interval 0.6 to 91 | percentage of participants | |
| Progression Free-Survival | 200 mg Vandetanib Adult | 4 | 95% Confidence Interval 0.6 to 91 | Months | |
| Progression Free-Survival | 300 mg Vandetanib Adult | 5.1 | 95% Confidence Interval 1.8 to 22.5 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02015065/results